Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Status:
Completed
Trial end date:
2009-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the
treatment of acute migraine in participants with stable vascular disease.
Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The
primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.